Investigating a potential treatment target for acute myeloid leukemia
Official title: The histone demethylase JMJD1C in human Acute Myeloid Leukemia
Funded at J. Craig Venter Institute, INC. · NIH-11176820 · Data updated 2026-11-12
This study is looking at how a specific protein called JMJD1C affects acute myeloid leukemia (AML) and whether combining treatments that target this protein with drugs that block the RAS pathway can help improve outcomes for patients, especially those with RAS mutations.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | J. Craig Venter Institute, INC. NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project start | May 1, 2024 |
| Project end | April 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $487,500 |
| NIH project number | 5R37CA229751-07 |
| Project ID | NIH-11176820 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with acute myeloid leukemia, particularly those with RAS mutations.
✕Less likely to help
Patients with acute myeloid leukemia who do not have RAS mutations may not benefit from this specific research.
What this research studies
This research focuses on understanding the role of JMJD1C, a histone demethylase, in acute myeloid leukemia (AML). The study aims to explore how targeting JMJD1C, particularly in combination with inhibitors of the RAS signaling pathway, can improve treatment outcomes for patients with AML, especially those with RAS mutations. Researchers will use mouse models and xenograft models to test the effectiveness of this combined therapy and investigate the underlying mechanisms of resistance to JMJD1C loss. The goal is to develop a more effective treatment strategy for AML patients.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with acute myeloid leukemia, potentially improving survival rates.
How similar studies have gone: Other research has shown promising results in targeting similar pathways in leukemia, suggesting that this approach may be effective.
Where this research is happening
-
J. Craig Venter Institute, INC.
La Jolla, United States Active
Researchers
- Principal investigator: Zhu, Nan — J. Craig Venter Institute, INC.
- Study coordinator: Zhu, Nan
Related research
Other NIH-funded projects on the same topics.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant
This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.
-
Targeting the protein housekeeping system in adult leukemia
Researchers are testing a new approach to treat acute myeloid leukemia by disrupting how AML cells manage their proteins, with the goal of helping patients live longer and healthier lives.
-
Understanding how epigenetic helper proteins drive AML and how to target them
A scientist team is studying how accessory proteins in gene-regulating complexes affect acute myeloid leukemia and whether they can be targeted for safer, more precise therapies.
-
Targeting FLVCR1-enabled choline use in a aggressive AML subtype
A new approach aims to block how a specific leukemia subtype (CG-AML) takes up choline to feed its growth, potentially slowing or stopping the disease.
-
Advancing CD70-targeted CAR-NK Therapy for AML
A patient-focused look at a new cell therapy that uses engineered NK cells to target AML by hitting CD70, aiming to reduce relapse with potentially fewer blood cell problems.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.